ZOREVUNERSEN shows promising seizure reductions for children with Dravet syndrome, with early clinical studies reporting sustained improvements in seizure frequency, quality of life, and adaptive behaviour, supporting continued development of a potential disease modifying therapy for Dravet syndrome patients globally.
Genetic Basis and Clinical Burden of Dravet Syndrome
Dravet syndrome is a rare developmental and epileptic encephalopathy usually caused by SCN1A haploinsufficiency leading to impaired sodium channel function and severe early onset epilepsy. Children with Dravet syndrome experience frequent convulsive seizures, developmental delay and elevated risks of sudden unexpected death in epilepsy compared with the broader epilepsy population. Current management relies largely on combinations of antiseizure medicines, yet many patients continue to experience substantial seizure burden and progressive neurodevelopmental difficulties. Zorevunersen has emerged as a potential targeted therapy aimed at correcting the underlying genetic mechanism rather than only suppressing seizures overall progression.
Trial Evidence for Zorevunersen in Dravet Syndrome
Researchers assessed zorevunersen in two phase 1 to 2a open label multicentre trials, MONARCH and ADMIRAL, enrolling patients aged 2 to 18 years with Dravet syndrome receiving standard antiseizure therapy. Overall, 81 patients entered the phase 1 to 2a studies and 75 continued into extension trials. Most adverse events were mild or moderate. Post lumbar puncture syndrome occurred in 25% of patients while elevated cerebrospinal fluid protein appeared in 45% during extensions. In those given 70 mg initially followed by doses up to 45 mg median convulsive seizure frequency changed from baseline by −58.82% to −90.91% during the first 20 months with consistent reductions across months.
Future Outlook for Treating Dravet Syndrome
The emerging evidence suggests zorevunersen could represent a disease modifying approach for Dravet syndrome by addressing the underlying SCN1A related sodium channel deficiency. Continued investigation in larger controlled trials will be essential to confirm efficacy clarify long term safety and determine how this therapy might integrate with existing antiseizure regimens in routine paediatric neurology practice worldwide going forward.
Reference
Laux L et al. Zorevunersen in children and adolescents with Dravet Syndrome. New England Journal of Medicine. 2026;394(10):969-82.
Featured image: Teeradej on Adobe Stock
